3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
8
Carcinoma, Merkel Cell
8
Neoplasms
7
Colorectal Neoplasms
7
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Neuroendocrine
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Interventions
Cisplatin
55
Radiotherapy
33
Cetuximab
25
Paclitaxel
23
Carboplatin
23
Radiotherapy, Intensity-Modulated
21
pembrolizumab
19
Docetaxel
17
Fluorouracil
16
Nivolumab
14
Drug Therapy
11
Radiation
9
Erlotinib Hydrochloride
8
Blood Specimen Collection
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Surveys and Questionnaires
6
atezolizumab
5
Surgical Procedures, Operative
5
Radiosurgery
5
Esophagectomy
5
Chemoradiotherapy
5
olaparib
4
dacomitinib
4
Leucovorin
4
Cyclophosphamide
4
Capecitabine
4
Biopsy
4
Afatinib
4
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Squamous Cell
×
avelumab
×
Clear all
NCT03494322
2026-05-20
EACH
University College, London
Phase 2
Completed
16 enrolled
NCT06869473
2025-03-14
AVEC-119
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
67 enrolled